Consequences of overutilization and underutilization of thrombolytic therapy in clinical practice

被引:12
|
作者
Ottesen, MM
Kober, L
Jorgensen, S
Torp-Pedersen, C
机构
[1] Gentofte Univ Hosp, Dept Cardiol, Copenhagen, Denmark
[2] Amager Hosp Copenhagen, Dept Internal Med, Copenhagen, Denmark
关键词
D O I
10.1016/S0735-1097(01)01198-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES The aim of this study was to evaluate the consequences, measured as mortality and in-hospital stroke, of the use of thrombolytic therapy among patients with acute myocardial infarction (AMI), who do not fulfill accepted criteria or who have contraindications to thrombolytic therapy (i.e., overutilization) and among patients who are withheld thrombolytic treatment despite fulfilling indications and having no contraindications (i.e., underutilization). BACKGROUND The implementation of treatment with thrombolysis in clinical practice is not in accordance with the accepted criteria from randomized studies. The consequence has been over- and underutilization of thrombolytic therapy among patients with AMI in clinical practice. The outcome of overutilization of thrombolytic therapy has not been described previously. METHODS We examined 6,676 consecutive patients admitted to the hospital with an AMI and recorded characteristics, in-hospital complications and long-term mortality. RESULTS Overall, 41% of the patients received thrombolytic therapy. Thrombolytic therapy was underutilized in 14.3% and overutilized in 12.9% of the patients. The use of thrombolytic therapy was associated with reduced mortality in every subgroup examined, including patients without an accepted indication, with an accepted indication and in patients with prior stroke. The risk ratio of in-hospital stroke was not increased in connection with thrombolytic therapy, not even in patients with Frier stroke (relative risk = 0.237, 95% confidence interval: 0.031 to 1.810, p = 0.17). CONCLUSIONS With the large benefit known to be associated with thrombolytic therapy and the favorable result of thrombolytic therapy in patients with contraindications observed in this study, we conclude that a formal evaluation of thrombolytic therapy in wider patient categories is warranted. (J Am Coll Cardiol 2001;37:1581-7) (C) 2001 by the American College of Cardiology.
引用
收藏
页码:1581 / 1587
页数:7
相关论文
共 50 条
  • [41] Clinical Impact of Underutilization of Adjuvant Therapy in Node Positive Gastric Adenocarcinoma
    Zhu, R.
    Liu, F.
    Grisotti, G.
    Irizarry, J. Perez
    Salem, R.
    Cha, C.
    Johung, K.
    Boffa, D.
    Zhang, Y.
    Khan, S. A.
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S205 - S205
  • [42] FUTURE-DIRECTIONS FOR CLINICAL INVESTIGATION IN THROMBOLYTIC THERAPY
    ROSS, J
    CIRCULATION, 1983, 68 (02) : 105 - 109
  • [43] Uncertainty and Its Consequences in Clinical Practice
    Wang, Shin-Yun
    Chan, Wing P.
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2015, 30 (11) : 1710 - 1712
  • [44] THROMBOLYTIC THERAPY FOR DEEP VENOUS THROMBOSIS - A CLINICAL REVIEW
    COMEROTA, AJ
    ALDRIDGE, SC
    CANADIAN JOURNAL OF SURGERY, 1993, 36 (04) : 359 - 364
  • [45] REVIEW OF CLINICAL PROBLEMS IN PATIENTS TREATED WITH THROMBOLYTIC THERAPY
    ROBERTS, W
    SOUTH AFRICAN MEDICAL JOURNAL, 1975, 49 (35): : 1427 - 1427
  • [46] Developmental haemostasis: consequences for clinical practice
    Ommen, H., V
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 37 - 37
  • [47] IMPORTANCE OF THE PHARMACOLOGICAL PROFILE OF THROMBOLYTIC AGENTS IN CLINICAL-PRACTICE
    ALPERT, JS
    AMERICAN JOURNAL OF CARDIOLOGY, 1991, 68 (16): : E3 - E7
  • [48] Use of thrombolytic agents to treat neonatal thrombosis in clinical practice
    Leong, Russell
    Patel, Jay
    Samji, Nasrin
    Paes, Bosco A.
    Chan, Anthony K. C.
    Petropoulos, Jo-Anne
    Bhatt, Mihir D.
    BLOOD COAGULATION & FIBRINOLYSIS, 2022, 33 (04) : 193 - 200
  • [49] Clinical applications of thrombolytic therapy: Strategies, techniques, and outcome
    Katzen, BT
    JOURNAL OF ENDOVASCULAR SURGERY, 1996, 3 (02): : 231 - 258
  • [50] New thrombolytic, anticoagulants, and platelet antagonists: The future of clinical practice
    Becker, RC
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 1999, 7 (02) : 195 - 220